Bioregnum channel feed – Endpoints News

Bioregnum channel feed

'We're in': Roche and Genentech join forces on a multibillion-dollar discovery pact with a brash AI upstart

4 years ago

The 2022 wave coming? Top analyst says Big Pharma will have more than $1T available to satisfy its growing appetite for biotech M&A

4 years ago

What were Endpoints readers tuning into this year? Here’s a look at our 15 most popular reports of the year (so far)

4 years ago

Are the stars lining up for a major M&A deal at Novartis?

4 years ago

Does biopharma support the Califf nom for FDA? Yeah, whatever

4 years ago

The renowned drug hunter, the Washington insider, the MIT strategist: How did one low-profile biotech enlist a dream team of top biotech advisors?

4 years ago

John Maraganore steps into a new role at an upstart biotech as the godfather phase of his career takes shape

4 years ago

The Endpoints 100 gives a C-suite thumbs down on 'crippling' price proposals and Aduhelm. Plus: Is anyone going to JP Morgan?

4 years ago

Care about R&D strategies? Have we got a summit for you

4 years ago

Is the biotech boom starting to fade? The roaring ‘20s starts to look a little fatigued. Plus: Top 5 deals, IPOs, pacts of Q3

4 years ago

So what happened with Novartis Gene Therapies? Here's your answer

4 years ago

Exclusives: Eli Lilly out to crash the megablockbuster PD-(L)1 party with 'disruptive' pricing; reveals cancer biotech buyout

4 years ago

#ESMO21 is looming, and we have a great group of experts lined up to help make sense of the news

4 years ago

Scoop: Adam Koppel's Bain team has another $1.9B to wager on life sci companies. And he likes their odds

4 years ago

Moderna soars into the ranks of the world's top pharma players, now worth 3 Regenerons

4 years ago

mGx M&A? Moderna execs are leveraging their Covid cash on gene editing, gene therapy deals

4 years ago

A global pandemic fiasco sets the stage for Tillman Gerngross to introduce his biotech unicorn to Wall Street

4 years ago

Biogen wasted no time in rolling out a ‘disease awareness’ campaign for Alzheimer's as an R&D marathon turns into a sprint. A top analyst awards gold, silver and bronze

4 years ago

Tillman Gerngross is betting well over $500M that the pandemic will never really end. Here’s the IPO pitch

4 years ago

With Moderna shares flying at a pandemic high, the market cap has now pierced the $100B mark, leapfrogging GlaxoSmithKline

4 years ago

IPOs and venture investing rock on in Q2 as SPAC attack takes a break. But what happened to the deals and M&A?

4 years ago

Is 9 years too long to run a confirmatory study for a drug like aducanumab? In Sarepta’s case, it isn’t enough time

4 years ago

The FDA has now poked a hornet's nest of controversy in the House. And that could sting Biogen's mega blockbuster quest in Alzheimer's

4 years ago

Just how sadly misguided is the FDA on aducanumab?

4 years ago

First page Previous page 3 4 567 8 9 Next page Last page